

# FACULTY FULL NAME: Omar Soliman Mohamed ElMasry

POSITION: Associate professor

## Personal Data

Nationality | Egyptian

Date of Birth | 18/6/1981

Department | Clinical laboratory sciences

Official IAU Email | Imam Abdulrahman Bin Faisal university

Office Phone No. | 31267

## Language Proficiency

Language	Read	Write	Speak
Arabic	mother tongue	mother tongue	mother tongue
English	Fluent	Fluent	Fluent
Others			

## Academic Qualifications (Beginning with the most recent)

Date	Academic Degree	Place of Issue	Address
20/7/2012	Ph.D.	University of Sheffield	UK
12/2006	Master	University of Alexandria	Egypt
05/2002	BSc.	University of Alexandria	Egypt

## PhD, Master or Fellowship Research Title: (Academic Honors or Distinctions)

PhD	<b>Studies on the role of AMP-activated protein kinase (AMPK) in breast cancer: potential implications for therapeutic targeting</b>
Master	<b>Consequences of the diabetic status on testicular oxidative damage in experimental animals: Role of antioxidant treatment.</b>

### Professional Record: (Beginning with the most recent)

Job Rank	Place and Address of Work			Date
Assistant Professor (equivalent to associate rank)	Applied Medical Chemistry Department	MRI, Univ. of Alexandria, Egypt	25/6/2023	Present (onleave)
Associate Professor	Clinical Laboratory Sciences dept.	IAU, KSA	23/1/2024	Present
Lecturer	Applied Medical Chemistry dept.	MRI, Univ. of Alexandria, Egypt	31/10/2012	25/6/2023
Assistant Lecturer	Applied Medical Chemistry dept.	MRI, Univ. of Alexandria, Egypt	20/12/2006	31/10/2012
Demonstrator	Applied Medical Chemistry dept.	MRI, Univ. of Alexandria, Egypt	8/1/2003	19/12/2006

### Administrative Positions Held: (Beginning with the most recent)

Administrative Position	Office	Date
Bridging program Coordinator	Clinical Laboratory Sciences department	2017-2020, appointed again 13/4/2022 (program on hold)

### Scientific Achievements

#### Published Refereed Scientific Researches

(In Chronological Order Beginning with the Most Recent)

#	Name of Investigator(s)	Research Title	Publisher and Date of Publication
1	Khaldoon Alsamman , Ali M. Alamri , Chittibabu Vatte , Amani Y. Owaidah, Fatimah Alhassan, Ruba Mubarak, Omar S. El-Masry.	Potential candidate genes for therapeutic targeting in chronic myeloid leukemia: A pilot study.	Asian Pac J Cancer Prev. 2023 Sep 1; 24(9):3077-3085. doi: 10.31557/APJCP.2023.24.9.3077.
2	Alshwareb A, Rashed M, Farooqi F, Alhabib I, Theruvan NB, El-	Clinical chemistry laboratory test overuse in a cardiology clinic: a single-center study.	J Med Life. 2023 Apr;16(4):540-545. doi: 10.25122/jml-2022-0338. PMID: 37305818; PMCID: PMC10251380.

	<b>Masry O.</b>		
3	<b>Omar S. El-Masry.</b>	Gene expression profile and presentation of novel gene variants of COX7B and COX7C in a cohort of patients with chronic myeloid leukemia.	Electronic Journal of General Medicine. 2023, 20(3), em468.
4	Faisal M Alzahrani, Asma A Al Faris, Layla A Bashawri, Fathelrahman Mahdi Hassan, <b>Omar S El-Masry</b> , Maryam A Aldossary, Osama Al Sultan, J Francis Borgio, Mohammed A Alsahli , Anne Goodeve.	<b>Phenotypic and Genotypic Signatures of VWF Exon 18 in Eastern Saudi Patients Previously Diagnosed with Type 1 von Willebrand Disease.</b>	International Journal of General Medicine 2022:15 5385–5394
5	Faisal M. Alzahrani, Jinan A. Alhassan, Abdullah M. Alshehri, Faraz A. Farooqi, Maryam A. Aldossary, Magdy K Abdelghany, Hafiz Ibrahim, <b>Omar S. El-Masry.</b>	The impact of SELP gene Thr715Pro polymorphism on sP-selectin level and association with cardiovascular disease in Saudi diabetic patients: A cross-sectional case-control study.	Saudi Journal of Biological Sciences. 2023, 30, 103579.
6	<b>Omar S. El-Masry</b> , Hussain Abdullah Alhawaj, Muaz O. Fagere, Amani Y. Owaidah, Aisha Alamri and Khaldoon Alsamman.	Oral intragastric DMBA administration induces acute lymphocytic leukemia and other tumors in male Wistar rats.	Journal of Experimental Pharmacology; 2022:14:87-96.
7	<b>Omar S. El-Masry</b> , Ali M. Alamri, Faisal Alzahrani, Khaldoon Alsamman.	ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia.	Heliyon; Heliyon 8 (2022) e09065. <a href="https://doi.org/10.1016/j.heliyon.2022.e09065">https://doi.org/10.1016/j.heliyon.2022.e09065</a>
8	<b>Omar S. El-Masry</b> , Abeer A. Alshwareb, Fatimah H. Alnasser, Sukainah G. al	Whole-transcriptome Bioinformatics revealed HTRA3, KRT8, KRT17 and	Journal of Taibah University Medical Sciences (2022) 17(5), 897-903.

	mishaal, Khaldoon M. Alsamman.	RHEX as novel targets in acute myeloid leukemia.	
9	<b>Omar S. El-Masry</b> & Muzaaheed.	Incidence and assessment of demography-related risk factors associated with pulmonary tuberculosis in Saudi Arabia: A retrospective analysis.	Pak J Med Sci March - April 2022 (Part-II) Vol. 38 No. 4
10	Muzaaheeda, Bashayer A. Alshehri, Ali A. Rabaan, <b>Omar S. El-Masry</b> , Sadananda Acharya, Faisal M. Alzahrani, Abbas Al Mutair, Saad Alhumaid, Jaffar A. Al-Tawfiq, Javed Muhammad, Amjad Khan, Kuldeep Dhama, Awad Al-Omari.	A 20-year retrospective clinical analysis of <i>Candida</i> infections in tertiary centre: Single-center experience.	J Infect Public Health. 2022 Jan; 15(1):69-74. doi: 10.1016/j.jiph.2021.11.014.
11	<b>El-Masry OS</b> , Goja A, Rateb M, Owaidah AY, Alsamman K.	RNA sequencing identified novel target genes for <i>Adansonia digitata</i> in breast and colon cancer cells.	Sci Prog. 2021 Jul-Sep; 104(3):368504211032084. doi: 10.1177/00368504211032084.
12	Muzaaheed M, <b>El-Masry OS</b> , Rabaan AA, Alzahrani F, Alomar A, Farooqi FA.	Comparative cross-sectional assessment of knowledge, attitude and practice among university students and employees towards the use of the microbiology laboratory equipment.	F1000Res. 2021 Feb 16; 10:117. doi: 10.12688/f1000research.49923.2.
13	<b>El-Masry OS</b> .	Simple statistical insights into the COVID-19 data of Saudi Arabia:	F1000Research 2021, 10:410. doi.org/10.12688/f1000research.52600.2

		figures prior to vaccination campaign	
14	<b>El-Masry OS,</b> Al-Amri AM, Alqatari A, Alsamman K.	RNA sequencing-based identification of potential targets in acute myeloid leukemia: A case report.	Biomed Rep. 2020 Nov; 13(5):42. doi: 10.3892/br.2020.1349. Epub 2020 Aug 27.
14	<b>El-Masry OS,</b> Brown BL, Dobson PRM.	AMPK Activation of Apoptotic Markers in Human Breast Cancer Cell Lines with Different p53 Backgrounds: MCF-7, MDA-MB-231 and T47D Cells.	Asian Pac J Cancer Prev. 2019 Dec 1; 20(12):3763-3770. doi: 10.31557/APJCP.2019.20.12.3763.
15	AlSadah K, S <b>El-Masry O,</b> Alzahrani F, Alomar A, Ghany MA.	Reporting Clinical Laboratory Critical Values: A Focus On The Recommendations Of The American College Of Pathologists.	J Ayub Med Coll Abbottabad. 2019 Oct-Dec; 31(4):612-618.
16	Alharbi, M., Yahia, M., Rashed, M. and <b>El-Masry,</b> <b>O.</b>	Association between Pentraxin-3 and Cardiac Troponin-I with Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction: Evaluation by Speckle Tracking Echocardiography.	(2019) World Journal of Cardiovascular Diseases, 9, 57-68. doi: 10.4236/wjcd.2019.92007
17	Alsamman K, <b>El-Masry OS.</b>	Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.	Oncol Rep. 2018 Oct; 40(4):2157-2162. doi: 10.3892/or.2018.6615.

18	<b>El-Masry, O.,</b> Youssef, A.	Targeting $\beta$ -catenin and cytochrome p450 (1B1) by Ellagic Acid in Colon Cancer Cell Lines: Implications for Treatment Applications.	<b>Bulletin of Egyptian Society for Physiological Sciences,</b> 2022; 38(2): 137-148. doi: 10.21608/besps.2018.8161
19	Yahia, M., <b>Elmasry, O.</b> and Ra'ouf, M.	The Relationship between Serum Pentraxin-3 Levels and Severity of Coronary Heart Disease.	(2018) <b>World Journal of Cardiovascular Diseases,</b> 8, 370-380. doi: 10.4236/wjcd.2018.87036.
20	Alsamman K, <b>El-Masry OS.</b>	Interferon regulatory factor 1 inactivation in human cancer.	<b>Biosci Rep.</b> 2018 May 8; 38(3):BSR20171672. doi: 10.1042/BSR20171672.
21	Alsamman K, Zhang X, Vatte C, Al Hamad M, <b>El-Masry OS,</b> Owaidah AY, Alzahrani F, Lin Y.	Novel IRF-1 Mutations in a Small Cohort of Leukaemia Patients From Saudi Arabia.	<b>Asian Pac J Cancer Prev.</b> 2017 Oct 26; 18(10):2795-2801. doi: 10.22034/APJCP.2017.18.10.2795
22	Alsamman K, <b>El-Masry OS.</b>	Developmental Phases of Anticancer Screening Models.	<b>Comb Chem High Throughput Screen.</b> 2017; 20(5):440-450. doi: 10.2174/1386207319666161226142822
23	Yousef AI, <b>El-Masry OS,</b> Abdel Mohsen MA.	Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of Small Interfering RNA.	<b>Asian Pac J Cancer Prev.</b> 2016; 17(2):743-8. doi: 10.7314/apjcp.2016.17.2.743.
24	Yousef AI, <b>El-Masry OS,</b> Yassin EH.	The anti-oncogenic influence of ellagic acid on colon cancer cells in leptin-enriched microenvironment.	<b>Tumour Biol.</b> 2016 Oct; 37(10):13345-13353. doi: 10.1007/s13277-016-5284-7.
25	<b>El-Masry OS,</b> Al-Sakkaf K, Brown BL,	Differential crosstalk between the AMPK and PI3K/Akt	<b>Oncol Rep.</b> 2015 Oct; 34(4):1675-80. doi: 10.3892/or.2015.4198.

	Dobson PR.	pathways in breast cancer cells of differing genotypes: Leptin inhibits the effectiveness of AMPK activation.	
26	El-Masry OS, Brown BL, Dobson PR.	Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds.	Oncol Lett. 2012 Jan; 3(1):224-228. doi: 10.3892/ol.2011.458.

### Refereed Scientific Research Papers Accepted for Publication

#	Name of Investigator(s)	Research Title	Journal	Acceptance Date

### Scientific Research Papers Presented to Refereed Specialized Scientific Conferences

#	Name of Investigator(s)	Research Title	Conference and Publication Date
1	Omar S. El-Masry & Khaldoon Alsamman	The regulated PI3K-related genes in acute and chronic leukemia patient samples: data from whole-genome RNA sequencing profiles	The PI3K/PTEN pathway: from basic science to clinical translation (British society of biochemistry), July 2019 – Buxton – UK - Poster
2	Omar S. El-Masry	Therapeutic targeting of AMP activated protein kinase (AMPK) in breast cancer: Hopes and limitation	78 <sup>th</sup> Harden Conference (Protein kinases in health and disease (British society of biochemistry) September 2015, Winchester – UK - Poster
4	Omar S. El-Masry	Abstract A79: Evidence that the antitumor effects of AMPK activation and crosstalk with the Akt pathway are dependent on the genetic profiles of human breast cancer cell types.	Molecular Cancer Therapeutics 10 (11 Supplement), A79-A79, 2011 (American Association for Cancer Research; AACR), San Francisco -USA
5	Pauline Dobson, John Collins, Omar El-Masry, Mary Goldring & Barry Brown	Activation of AMP-activated protein kinase represses chondrocyte proliferation	Endocrine Abstracts (2009) 19 P21. The annual meeting of the British Society of Endocrinology

### Completed Research Projects

#	Name of Investigator(s) (Supported by)	Research Title	Report Date
1	Omar S. El-Masry & Khaldoon Alsamman	The role of p62 in chemo-resistance in ovarian cancer	2016 (CAMS)
2	Omar S. El-Masry & Khaldoon Alsamman	Design and Validation of therapeutic agents for leukemia based on RNA sequencing-Whole genome expression profile	2017 (CAMS-2017-099; Completed)

### Current Researches

#	Research Title	Name of Investigator(s)
1	Design and Validation of therapeutic agents for leukemia based on RNA sequencing-Whole genome expression profile (phase 2).	Omar S. El-Masry & Khaldoon Alsamman, Dr. Faisal ALZahrani, Dr. Ali Alamri
2	Nanoformulations of Adiponectin and Caffeoylquinic Acid Derivatives as Promising Therapeutic Agents in Type 2 Diabetes and Obesity, In Vitro and In Vivo Studies	Dr. Mohamed Elsaadany & Dr. Omar ElMasry

### Contribution to Scientific Conferences and Symposia

#	Conference Title	Place and Date of the Conference	Extent of Contribution
1	ECM/Redox Signalling Axis: From Cancer to Tissue Repair and Smarter Regenerative Therapies	Biochemistry Focus ECR webinar series, organized by Biochemical society, UK 23/1/2024	Attendance
2	New advances in DNA structure, repair, and protein quantification	Biochemistry Focus ECR webinar series, organized by Biochemical society, UK 11/11/2022	Attendance
3	2nd Annual Saudi Laboratory and Diagnostic Congress	Virtual meeting- organized by Saudi Society for Clinical Laboratory Sciences 20-22 /2/2022	Attendance

4	Reprogramming of the epigenome in embryogenesis	<b>Webinar- organized by Biochemical society, UK 3/9/2020</b>	Attendance
5	The PI3K/PTEN pathway: from basic science to clinical translation	<b>The Palace Hotel, Buxton, UK 18-20 July 2019</b>	Poster presentation
6	A symposium on Laboratory medicine: current aspects and future prospects	<b>King Fahd University Hospital 19-20/9/2016</b>	attendance
7	78 <sup>th</sup> Harden conference: Protein kinases in health and disease	<b>Winchester, UK 15-18/9/2015</b>	Poster presentation
8	Annual Scientific Research Update	<b>University of Dammam 5-7/4/2015</b>	attendance
9	Advanced hematology and transfusion sciences symposium	<b>King Fahd University Hospital 27-29/4/2014</b>	attendance
10	Advanced hematology and transfusion symposium (immediate morphology workshop and intermediate transfusion workshop)	<b>King Fahd University Hospital 30/4/2014</b>	attendance
11	The first annual meeting of the Saudi immunology group	<b>Holiday Inn. Alkhobar 13/12/2015</b>	attendance
12	Conference on clinical, pathologic and molecular medicine (University of Dammam & Wayne state University)	<b>King Fahd University Hospital 15-19/2/2015</b>	attendance
13	The American association of cancer research (AACR) meeting on molecular targets and cancer therapeutics	<b>San Francisco, USA (12-16/11/2011).</b>	Poster presentation
14	The British Society of Endocrinology (BSE) annual meeting	<b>Harrogate, UK, 16-19/03/2009.</b>	Poster presentation
15	The UK mesenchymal stem cell meeting, University of Sheffield	<b>Sheffield, UK, 08/01/2009.</b>	Attendance
16	The 11th conference of the medical research	<b>Alexandria, Egypt</b>	Attendance

	institute, University of Alexandria	(2005)	
17	The 12th conference of the medical research institute, University of Alexandria (Advances in Medical Research)	Alexandria, Egypt (2006)	Attendance

<b>Academic development workshops</b>			
1	10 Effective Formative Assessment Techniques for the Classroom	Deanship of academic development, Imam Abdulrahman Bin Faisal University (2023)	Attend ance
2	Legal and financial aspects in universities	Faculty and leadership development centre (FLDC), University of Alexandria, Egypt (2022) (online attendance)	Attend ance
3	Competing for research funds	Faculty and leadership development centre (FLDC), Cairo University, Egypt (2022) (online attendance)	Attend ance
4	Exams and students systems evaluation	Faculty and leadership development centre (FLDC), Cairo University, Egypt (2022) (online attendance)	Attend ance
5	10 effective formative assessment techniques for the classroom	Deanship of academic development, Imam Abdulrahman Bin Faisal University (2022)	Attend ance
6	Academic Supervision	The Vice Presidency for Academic Affairs at Imam Abdulrahman bin Faisal University (2021)	Attendan ce
7	Orientation on DQAA applications electronic	Deanship of quality and academic accreditation, Imam Abdulrahman Bin Faisal University (2021)	Attendan ce
8	From urgent distant learning professional distant learning	Deanship of academic development, Imam Abdulrahman Bin Faisal University (2020)	Attend ance

1	Active Learning in Higher Education	Deanship of academic development, Imam Abdulrahman Bin Faisal University (2020)	Attendance
2	Author Workshop in Scholarly Publishing	Abdulrahman Bin Faisal University(2017)	Attendance

### Peer review activities

<b><u>Research title</u></b>	<b><u>Journal</u></b>	<b><u>Calendar Year</u></b>
The prognostic marker KRT81 is involved in suppressing CD8+ T cells and predicts immunotherapy response for triple-negative breast cancer	<b>Cancer Biology &amp; Therapy</b>	2024
Implication of Genomic Alterations of Programmed Death Ligand 1 (PD-L1) in the progression of Type 1 Diabetes	<b>Journal of the Medical Research Institute</b>	2024
The actin motor protein Myosin 6 contributes to cell migration and expression of GIPC1 and Septins in breast cancer cells	<b>Cancer Management and Research</b>	2024
Significant association between genetic polymorphism of Insulin-Like Growth Factor-2 mRNA Binding Protein-2 and Type -2 Diabetes Mellitus: A population-based case-control study	<b>Journal of Clinical Laboratory Analysis</b>	2024
Chitosan-Loaded Piperlongumine nanoparticles and Kaempferol Enhance the Anti-Cancer Action of Doxorubicin in Targeting of Ehrlich Solid Adenocarcinoma: in-vivo and In-silico Modeling Study	<b>Medical Oncology</b>	2023
Potential effect of Chloroquine and Propranolol combination to treat colorectal and triple-negative breast cancers	Scientific reports	2023
Building network-based multi-class classifier and its application to gene regulatory network-based acute leukemia cell line classification	<b>Computational and Structural Biotechnology Journal</b>	2023
Construction of a regulatory network presenting how circRNAs affecting m6A modification after p62 knockdown in acute myeloid leukemia	<b>Gene</b>	2023
Bioinformatics Analysis of the Endoplasmic Reticulum Stress-Related Prognostic Model and Immune Cell Infiltration in Acute Myeloid Leukemia	<b>Hematology</b>	2022
A1 adenosine receptor antagonist induces cell apoptosis in KYSE-30 and YM-1 esophageal cancer cell lines	<b>Biomedicine</b>	2022

The clinical value of SLC7A5 associated with molecular immune characterization in breast cancer	<b>Cancer Management and Research</b>	2022
miR-let-7a inhibits sympathetic nerve remodeling after myocardial infarction by down-regulating the expression of nerve growth factor	<b>Experimental and Therapeutic Medicine</b>	2021
Alexander disease caused by de novo mutations in the GFAP gene: clinical, fMRI and functional analyses	<b>Molecular Medicine Reports</b>	2021
Lactate Dehydrogenase Reduction Through Restoration of P53 in Breast Cancer Cells in Response to Melatonin and Vitamin D3 Combination Therapy	<b>OncoTargets and Therapy</b>	2021
GLUCOSE TRANSPORTERS AS MARKERS OFDIAGNOSIS ANDPROGNOSIS IN CANCER DISEASES: GLUCOSE TRANSPORTERS AND CANCERS	<b>Oncology Reviews</b>	2021
Clinicopathological significance of tumor-infiltrating lymphocytes in estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer	<b>Molecular and Clinical Oncology</b>	2020
Effect of aquaporin inhibition on cryodamage associated with freezing in MDA-MB-231 and MCF-7 breast cancer cell lines	<b>Oncology Letters</b>	2020
IDO inhibitors combined with Stat3-siRNAs delivered by attenuated Salmonella inhibit breast cancers	<b>Oncology Letters</b>	2020
Triple-negative breast cancer with unmutated PIK3CA&ndash;mutated TP53&ndash;high Ki67 expression revealed early disease onset in Korean patients	<b>Oncology Letters</b>	2020
Prognostic influence of the combination of preoperative fibrinogen and neutrophil-to-lymphocyte ratio for resectable breast cancer.	<b>Oncology Letters</b>	2020
Effect of aquaporin inhibition on cryodamage associated with freezing in MDA-MB-231 and MCF-7 breast cancer cell lines	<b>Oncology Letters</b>	2020
An Emerging View of the Role of Estrogen Related Receptor alpha in the Complication of Non-Small Cell Lung Cancers	<b>Oncology Letters</b>	2020
The PAD4 inhibitor GSK484 enhances the radiosensitivity of triple-negative breast cancer	<b>Oncology Letters</b>	2020

Stereospecific inhibition of AMPK by (R)-crizotinib induces differentiation of cancer and cancer stem cell-like cells	Oncology Reports	2020
Inhibition of HMGB1 reduces high glucose-induced BMSCs apoptosis via activation of AMPK and regulation of mitochondrial functions	Journal of physiology and biochemistry	2020
In vitro evaluation of anticancer properties of exopolysaccharides from different lactic acid bacteria in human colon cancer and breast cancer cell lines	Scientific Reports	2020
miR-20a-5p regulated radio-resistance in triple negative breast cancer by repressing ACSL4-mediated ferroptosis	Experimental and Therapeutic Medicine	2020
Tetrandrine attenuates left ventricular dysfunction in rats with myocardial infarction	Experimental and Therapeutic Medicine	2020
Synergistic role of thymoquinone on anticancer activity of 5-fluorouracil in triple negative breast cancer cells	Experimental and Therapeutic Medicine	2020
LINC01128 participates the progression of pre-eclampsia by regulating miR-16	Experimental and Therapeutic Medicine	2020
Hypothermic anoxic-reoxygenated fibroblasts may inhibit the intercellular coupling in neonatal rat cardiomyocytes	Experimental and Therapeutic Medicine	2020
Fas regulates apoptosis and migration of trophoblast cells by targeting NF-kappaB	Experimental and Therapeutic Medicine	2020
Bilateral primary rare types of breast cancer : a case report and literature review	Molecular and Clinical Oncology	2020
Primary acinic cell carcinoma of the breast associated with poor outcome: a case report and literature review	Molecular and Clinical Oncology	2020
Harmine suppresses the malignant phenotypes and PI3K activity in breast cancer	Molecular Medicine Reports	2020
Neutrophil-to-lymphocyte ratio predicts the severity of motor impairment in cerebral palsy children living at home and the rehabilitation center: A comparative study	Biomedical Reports	2020

Glucose homeostasis maintaining in toll-like receptor 2 knockout mice fed with high-fat diet: involvement of macrophage polarization	Biomedical Reports	2020
mesenchymal stem-like cells: phenotypes and functions in tumor microenvironment development	Oncology Letters	2020
Unnatural amino acid directed site-specific fluorescent labeling of NMDA receptors	<b>International Journal of Molecular Medicine</b>	2020
Identification of coexpression modules and hub genes of retinoblastoma via coexpression analysis and protein-protein interaction networks	<b>Molecular Medicine Reports</b>	2019
Identification of crucial SMAD genes with clinicopathological and prognostic significance in breast tumor microenvironment through bioinformatics analysis	Molecular Medicine Reports	2019
Cryptotanshinone stimulates T cell activation via the PI3K/AKT pathway	<b>Experimental and Therapeutic Medicine</b>	2019
Long-term outcomes of incidental gallbladder carcinoma without additional resection: a single institution experiment	<b>Molecular and Clinical Oncology</b>	2019
Effect of alteration/deficiency in activation 3 on the proliferative and invasive phenotypes of non-small cell lung cancer cells	<b>International Journal of Oncology</b>	2019
Identification of key biomarkers and potential molecular mechanisms in lung cancer by bioinformatics analysis	Oncology Letters	2019
Role of H <sub>2</sub> S-mediated ROCK inhibition in protection of total flavones of rhododendron against myocardial ischemic injury	<b>Experimental and Therapeutic Medicine</b>	2018
Altered expression of 17-beta-hydroxysteroid dehydrogenase type 2 and its prognostic significance in non-small cell lung cancer.	<b>International Journal of Oncology</b>	2018
Plasma ALU-247, ALU-115 and cfDNA integrity as diagnostic and prognostic biomarkers for breast cancer."	<b>Applied Biochemistry and Biotechnology</b>	2018
CPEB4 influences the proliferation and apoptosis via the PI3K / AKT and Caspase signaling pathways in chronic myeloid leukemia cells	Oncology Letters	2018
Down-regulation of $\beta$ -catenin blocks profibrotic via Wnt2 signaling in human keloid fibroblast	Tumor Biology	2017

## Membership of Scientific and Professional Societies and Organizations

- Associate member of the American society for cancer research (AACR) (2010-2016)
- Early career member of the British society for biochemistry (Biochemical Society) and Federation of the European Biochemical Societies (2011- current)

## Teaching Activities

### Undergraduate

#	Course/Rotation Title	No./Code	Extent of Contribution (no. of lectures/Tutorials. Or labs, Clinics)
1	Medical Instrumentation	MLT-213	Teaching & coordination (2015-present) Coordinated the course from 2017/2018 – 2019/2020
2	Laboratory Instrumentation (bridging)	MLT-203B	Teaching & coordination (2015/2016 – 2018/2019 term 1)
3	Clinical Chemistry I	MLT-222	Teaching (2015-2016 – present)
4	Clinical Chemistry II	MLT-312	Coordination and teaching (2016-2017- present) coordinated the course 2019-2020 - present
5	Clinical Chemistry I (bridging)	MLT-304B	Coordination and teaching (204/2015 – 2018/2019 term 2)
6	Introduction to clinical chemistry (bridging)	MLT-103B	Coordination and teaching (2017/2018 term 2)
7	Clinical chemistry II (bridging)	MLT-308B	Coordination and teaching (2016/2017 – 2019/2020 term 1)
8	Advance Molecular Biology (Bridging)	MLT-310B	Teaching (2017/2018 term 2)
9	Clinical chemistry hospital rotation	MLT-422	Coordination and teaching (2015/2016- present) coordinating the course since 2019/2020 - present
10	Clinical chemistry hospital rotation (bridging)	MLT-403B	Coordination and teaching (2016/2017 – 2019/2020 term 2)
11	Research methodology	HIMT-325	Coordination and teaching (2015/2016- present) coordinating the course since 2019/2020 term 2 -present
12	Molecular biology	MLT-224	Teaching (2018/2019 term 2 – present)
13	Research projects	MLT-424	Students supervision (2016/2017 – present)
14	Diagnostic Histotechnology & Cytology Rotation	MLT-413	Teaching (2020/2021 – present)

### Postgraduate

#	Course/Rotation Title	No./Code	Extent of Contribution (no. of lectures/Tutorials. Or labs, Clinics)
1	Pathology and molecular basis of disease	CLS-701	Teaching (2019/2020 term 1 – present)
2	Research methodology	CLS-702	Teaching (2019/2020 term 1 – present)
3	Research methodology	MLT-835	Teaching (2016/2017 / 2019/2020 term 1)
4	Student seminar-I	MLT-704	supervision
5	Student seminar-II	MLT-705	supervision
6	Thesis (lecture)	MLT-799	supervision
7	Master Degree Thesis	MLT -841	supervision
8	Medical Ethics	MLT-823	Teaching (2018/2019 term 2)
9	Techniques of Molecular Biology	MLT-812	Teaching (2018/2019 term 1)
10	Lab Management & Quality Control Assurance	MLT-811	Teaching (2016/2017)
11	Path & Molecular Basis of Disease	MLT-821	Teaching (2016/2017 – 2018/2019)
12	Communication Skills	MLT-822	Coordination and teaching (2016/2017)

### Supervision of Master and/or PhD Thesis

Degree Type	Title	Institution	Date
Master: Jinan Abdulhameed Alhassan (co supervisor)	Soluble sP-selectin and P-selectin Thr715Pro polymorphism association with cardiovascular disease in type 2 diabetes mellitus among Saudis from Eastern Saudi Arabia	CLS, Imam Abdulrahman Bin Faisal University	2018 - finished and published

				i s h e d
	<b>Master: Haya Salem Alqahtani (supervisor)</b>	<b>The Cytogenetic  and Immunophenotypic profile among Saudi Acute Myeloid Leukemia patients: Retrospective analysis for past five years in single center</b>	CLS, Imam Abdulrahman Bin Faisal University	2 0 2 2
	<b>Master: Safaa Mohamed AlQaisom (supervisor)</b>	<b>Circulating microRNA-92a as biomarker  of cardiovascular disease in CKD patients</b>	CLS, Imam Abdulrahman Bin Faisal University	2 0 2 2
	<b>Master: Maram Khaled Albaqmi (supervisor)</b>	<b>Identification of Thrombomodulin C1418T Gene polymorphism in Patients with Myocardial Infarction in Easter  n province of Saudi Arabia</b>	CLS, Imam Abdulrahman Bin Faisal University	2 0 2 4
	<b>Master: Fatima Alhussain (supervisor)</b>	<b>Quantitative validation of RNA sequencing gene expression levels of COX 7B, RPL34, RPL36A, and LDB1 in CML patients' blood by quantitative qRT- PCR: Analysis of SNP/INDEL variants</b>	CLS, Imam Abdulrahman Bin Faisal	2 0 2 4

## Ongoing Research Supervision

Degree Type	Title	Institution	Date
Master: Amjad Saleh Alatawi (supervisor)	The role of set binding factor 1 (SBF1) in breast and colon cancer: Implications of activation and overexpression in cell line models	CLS, Imam Abdulrahman Bin Faisal	2025

## Administrative Responsibilities, Committee and Community Service (Beginning with the most recent)

### Administrative Responsibilities

From	To	Position	Organization
2017	2020	Bridging program Coordinator	Clinical Laboratory Sciences department

### Committee Membership

From	To	Position	Organization
2023	present	Head of quality of exams and assessment committee	Clinical Laboratory Sciences department
2021	2023	Member of examination committee	Clinical Laboratory Sciences department
2024	present	Member of planning and development committee	Clinical Laboratory Sciences department
2023	present	Member of postgraduate studies committee	Clinical Laboratory Sciences department
2022	2023	Member of CLS master program academic accreditation	Clinical Laboratory Sciences department

			committee (head of vision, mission, and goals subcommittee)	
	202 1	202 1	Member of postgraduate admission committee	Clinical Laboratory Sciences department
	202 0	202 0	A member of programs restructuring and reviewing committee	Clinical Laboratory Sciences Department
	201 6	202 1	Member of quality and accreditation committee (Team of excellence)	Clinical Laboratory Sciences Department

**Personal Key Competencies and Skills: (Computer, Information technology, technical, etc.)**

	<ul style="list-style-type: none"> <li>• <i>Cell culture techniques</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Real-time Polymerase Chain Reaction (qRT-PCR).</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Conventional Polymerase Chain Reaction (PCR).</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Western Blotting.</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Flow cytometry</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Cell transfection protocols</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Immunocyto/histochemistry.</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Enzyme-Linked Immunosorbent assays (ELISA).</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Basic biochemical techniques.</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Analysis/interpretation of bioinformatics data</i></li> </ul>
	<ul style="list-style-type: none"> <li>• <i>Experience with Animal model-based research</i></li> </ul>

# Reviewer Certificate

# 2024

**Dr Omar S. El-Masry**

has reviewed 1 manuscript(s) in the journal

**Cancer Management and Research**

Thank you for your contribution to the journal. The dedication of our reviewers is invaluable in safeguarding the quality and high standard of academic integrity in the research we publish.

**Dovepress**  
open access to scientific and medical research



Computational and Structural  
Biotechnology Journal



# Certificate of Reviewing

Awarded for 1 review in October 2023  
presented to

**OMAR S EL-MASRY**

in recognition of the review contributed to the journal

The Editors of Computational and Structural Biotechnology Journal



# Reviewer Certificate

# 2023

**Dr Omar S. El-Masry**

has reviewed 2 manuscript(s) in the journal

**International Journal of General Medicine**

Thank you for your contribution to the journal. The dedication of our reviewers is invaluable in safeguarding the quality and high standard of academic integrity in the research we publish.

**Dovepress**  
open access to scientific and medical research





Outlook

---

## Thank you for reviewing - Journal of Clinical Laboratory Analysis

---

**From** JCLA Editorial Office <onbehalf@manuscriptcentral.com>

**Date** Sat 8/24/2024 5:25 AM

**To** Omar soliman Mohamed Elmasry <oselmasry@iau.edu.sa>

تحذير: هذه الرسالة مرسله من خارج جامعة الامام عبد الرحمن بن فيصل. يرجى توخي الحذر عند فتح المرفقات أو النقر فوق الارتباطات أو الاستجابة لطلبات المعلومات

CAUTION: This message is originated outside of "IAU" domain. Please use caution when opening attachments, clicking links or responding to requests for information.

24-Aug-2024

Dear Dr El-Masry:

Thank you for reviewing manuscript # JCLA-24-400 entitled "Significant association between genetic polymorphism of Insulin-Like Growth Factor-2 mRNA Binding Protein-2 and Type -2 Diabetes Mellitus: A population-based case-control study" for the Journal of Clinical Laboratory Analysis.

On behalf of the Editors of the Journal of Clinical Laboratory Analysis, we appreciate the voluntary contribution that each reviewer gives to the Journal. We thank you for your participation in the online review process and hope that we may call upon you again to review future manuscripts.

In appreciation of your review, we are pleased to offer you a 30% discount on Wiley books.

Visit <https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.wiley.com%2F&data=05%7C02%7C0selmasry%40iau.edu.sa%7C3e37152d51a64875147f08dcc461bf08%7C2c86bbfc8d0441ffa83a942f075e0f60%7C0%7C0%7C638601171299211865%7CUnknown%7CTWFpbGZsb3d8eyJWljoMC4wLjAwMDAiLCJQJjoiV2luMzliLjBtIl6Ik1haWwiLCJXVCi6Mn0%3D%7C0%7C%7C%7C&sdata=sTpvIk2%2F%2F07y%2B%2BuDQct8icLuK4i9np1TwboRzPY9Wfo%3D&reserved=0> and use code JRREV in the promotion code field. Discount excludes major reference works.

Sincerely,

Dr Le Yu

Co-Editor-in-Chief, Journal of Clinical Laboratory Analysis

jcla.eo@wiley.com





Outlook

---

**Thank You for Reviewing MEDO-D-23-02344**

---

**From** em.medo.0.87c056.84a63c26@editorialmanager.com  
<em.medo.0.87c056.84a63c26@editorialmanager.com>  
on behalf of  
Medical Oncology (MEDO) <em@editorialmanager.com>  
**Date** Fri 12/1/2023 7:08 AM  
**To** Omar soliman Mohamed Elmasry <oselmasry@iau.edu.sa>

تحذير: هذه الرسالة مرسله من خارج جامعة الامام عبد الرحمن بن فيصل. يرجى توخي الحذر عند فتح المرفقات أو النقر فوق الارتباطات أو الاستجابة لطلبات المعلومات  
CAUTION: This message is originated outside of "IAU" domain. Please use caution when opening attachments, clicking links or responding to requests for information.

MEDO-D-23-02344  
Chitosan-Loaded Piperlongumine nanoparticles and Kaempferol Enhance the Anti-Cancer Action of Doxorubicin in Targeting of Ehrlich Solid Adenocarcinoma: in-vivo and In-silico Modeling Study  
Medical Oncology

Dear Dr. El-Masry,

Thank You for your review of this manuscript.

You can access your review comments and the decision letter (when available) by logging onto the Editorial Manager site.

Your username is: oselmasry@iau.edu.sa

If you forgot your password, you can click the 'Send Login Details' link on the EM Login page at <https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.editorialmanager.com%2Fmedo%2F&data=05%7C01%7Coselmasry%40iau.edu.sa%7C3fc7a0e1c4b845bfe24b08dbf2a0dfeb%7C2c86bbfc8d0441ffa83a942f075e0f60%7C0%7C0%7C638370544990902131%7CUnknown%7CTWFpbGZsb3d8eyJWljojMC4wLjAwMDAiLCJQJjoiV2luMzliLCJBTiI6I1haWwiLCJXVCi6Mn0%3D%7C3000%7C%7C&sdata=0%2BNjkeJt1NDCG8CzxJoDnKISAlg7ycs8BMtv%2FoORerY%3D&reserved=0>.

Kind regards,  
Brandy Yeater  
Springer Journals Editorial Office  
Medical Oncology

This letter contains confidential information, is for your own use, and should not be forwarded to third parties.

Recipients of this email are registered users within the Editorial Manager database for this



---

**Manuscript was Reviewed by Reviewer (#JMALEXU-2408-1023 (R1))**

---

**From** Journal of the Medical Research Institute <jssub@ekb.eg>

**Date** Fri 8/16/2024 9:18 AM

**To** Omar soliman Mohamed Elmasry <oselmasry@iau.edu.sa>

تحذير: هذه الرسالة مرسله من خارج جامعة الامام عبد الرحمن بن فيصل. يرجى توخي الحذر عند فتح المرفقات أو النقر فوق الارتباطات أو الاستجابة لطلبات المعلومات  
**CAUTION:**This message is originated outside of "IAU" domain. Please use caution when opening attachments, clicking links or responding to requests for information.

Manuscript ID: JMALEXU-2408-1023 (R1)

Manuscript Title: **Implication of Genomic Alterations of Programmed Death Ligand 1 (PD-L1) in the progression of Type 1 Diabetes**

Dear **Omar Elmasry**

Thank you for reviewing the above-mentioned manuscript for the "**Journal of the Medical Research Institute**".

On behalf of the Editor, we appreciate the contribution that each reviewer gives to the Journal.

We thank you for your participation in the online review process and hope that we may call upon you again to review our future manuscripts.

Please do not hesitate to contact us if I can be of any assistance.

Editorial Office of **Journal of the Medical Research Institute**

 Print  Close

## 8694183: Thank you for submitting your reviewer report

Poovitha Ponnambalam  
<pponnambal@wiley.com>

Fri 12/29/2023 4:25 AM

To: Omar soliman Mohamed Elmasry  
<oselmasry@iau.edu.sa>

تحذير: هذه الرسالة مرسله  
من خارج جامعة الامام عبد  
الرحمن بن فيصل. يرجى  
توخي الحذر عند فتح  
المرفقات أو النقر فوق  
الارتباطات أو الاستجابة  
لطلبات المعلومات

**CAUTION:**This message is originated outside of "IAU" domain. Please use caution when opening attachments, clicking links or responding to requests for information.

Dear Dr. El-Masry,

Thank you for submitting your reviewer report on 8694183 titled "Overuse of coagulation studies in the Emergency Department" by Abdulaziz Alohal, and for taking the time and effort to review this manuscript for Emergency Medicine International.

Kind regards,  
Poovitha Ponnambalam  
Emergency Medicine International



10/20/21, 7:32 PM

Mail - Omar soliman Mohamed Elmasry - Outlook

ONCOL - Oncology Reviews [paper #561] - Article Review Acknowledgement

Ms. Paola Granata <paola.granata@pagepress.org>

Mon 10/4/2021 9:35 PM

To: Omar soliman Mohamed Elmasry <oselmasry@iau.edu.sa>

تحذير: هذه الرسالة مرسلة من خارج جامعة الإمام عبد الرحمن بن فيصل. يرجى توخي الحذر عند فتح العرفقات أو النقر فوق الارتباطات أو الاستجابة لطلبات المعلومات

**CAUTION:**This message is originated outside of "IAU" domain. Please use caution when opening attachments, clicking links or responding to requests for information.

Dear Omar S. El-Masry:

Thank you for completing the review of the submission, "GLUCOSE TRANSPORTERS AS MARKERS OF DIAGNOSIS AND PROGNOSIS IN CANCER DISEASES: GLUCOSE TRANSPORTERS AND CANCERS," for Oncology Reviews. We appreciate your contribution to the quality of the work that we publish.

Ms. Paola Granata  
PAGEPress Office, Pavia  
paola.granata@pagepress.org

Managing Editor

---

[Oncology Reviews](#)



**Dovepress**  
open access to scientific and medical research

---

## To whom it may concern

Dr Omar S El-Masry has reviewed 1 submission in the journal *OncoTargets and Therapy* (journal Impact Factor: 4.147) during 2021.

This contribution is greatly appreciated.

Regards

**Angela Jones**

**General Manager, Dove Medical Press Ltd**

Dove Medical Press (NZ) Ltd, 44 Corinthian Drive, Albany, Auckland, New Zealand

PO Box 300-008, Albany, Auckland, 0752, New Zealand

p +649 443 3060 f +649 443 3061 e [info@dovepress.com](mailto:info@dovepress.com)

**Live Chat** [https://www.dovepress.com/live\\_help/](https://www.dovepress.com/live_help/)

**Twitter** <https://twitter.com/DovePress>

[www.dovepress.com](http://www.dovepress.com) - open access to scientific and medical research

---

[www.dovepress.com](http://www.dovepress.com)

Dove Medical Press (NZ) Ltd, 44 Corinthian Drive, Albany, PO Box 300-008, Albany, Auckland 0752, New Zealand  
tel +64 9 443 3060 - fax +64 9 443 3061 - email [info@dovepress.com](mailto:info@dovepress.com)



10/31/2020

Mail - Omar soliman Mohamed Elmasry - Outlook

Scientific Reports: Thank you for your review on "In vitro evaluation of anticancer properties of exopolysaccharides from different lactic acid bacteria in human colon cancer and breast cancer cell lines"

Scientific Reports <srep@nature.com>

Thu 10/22/2020 10:47 PM

To: Omar soliman Mohamed Elmasry <oselmasry@iau.edu.sa>

1 attachments (1 MB)

Your review report for Scientific Reports.pdf;

تحذير: هذه الرسالة مرسله من خارج جامعة الامام عبد الرحمن بن فيصل. يرجى توخي الحذر عند فتح المرفقات أو النقر فوق الارتباطات أو الاستجابة لطلبات المعلومات

**CAUTION:**This message is originated outside of "IAU" domain. Please use caution when opening attachments, clicking links or responding to requests for information.

Ref: "In vitro evaluation of anticancer properties of exopolysaccharides from different lactic acid bacteria in human colon cancer and breast cancer cell lines"

Dear Dr Omar S. El-Masry,

Thank you for submitting your report to Scientific Reports. We greatly value the time and effort you put into reviewing the manuscript. Please take a moment to [let us know](#) if you'd be interested in receiving feedback on your review reports.

We've attached a copy of the report for your reference. You can also use this email to verify your review activity with third party websites, such as Publons and ORCID.

If you have opted to have your name included in our [monthly list of reviewers](#) on the Scientific Reports website, we will add it in the first week of November.

We'll email you the decision on the manuscript as soon as it is made. Meanwhile, we hope that we can continue to benefit from your expertise in the future.

Kind regards,

Peer Review Advisors  
Scientific Reports



6/21/2018

Thank You for Reviewing #ABAB-D-18-00590

**Thank You for Reviewing #ABAB-D-18-00590**

em.abab.8762.5c080a.049a1501@editorialmanager.com on behalf of Xiluan Yan

[em@editorialmanager.com]

**Sent:** Thursday, June 21, 2018 3:20 AM

**To:** Omar soliman Mohamed Elmasry

Dear Dr. El-Masry

Thank you for your review of the manuscript ABAB-D-18-00590 for Applied Biochemistry and Biotechnology. We greatly appreciate your assistance.

With kind regards,  
The Editorial Office  
Applied Biochemistry and Biotechnology



7/17/2018

Thank you for submitting your review of Manuscript ID TUB-17-0410 for Tumor Biology - Omar soliman Mohamed Elmasry

## Thank you for submitting your review of Manuscript ID TUB-17-0410 for Tumor Biology

Tumor Biology <onbehalf+jrados+uic.edu@manuscriptcentral.com>

Thu 3/23/2017 10:12 PM

To: Omar soliman Mohamed Elmasry <oselmasry@uod.edu.sa>

24-Mar-2017

Dear Dr. El-Masry:

Thank you for reviewing manuscript # TUB-17-0410 entitled "Down-regulation of  $\beta$ -catenin blocks profibrotic via Wnt2 signaling in human keloid fibroblasts" for Tumor Biology.

In recognition of your continued support, Tumor Biology and our publisher SAGE are pleased to offer you 60 days complimentary online access to all journals published by SAGE. Register at <https://emea01.safelinks.protection.outlook.com?url=www.uk.sagepub.com%2Freviewersaccess&data=01%7C01%7C0selmasry%40uod.edu.sa%7Cb8cd7ef737e144cb8e5d08d4729e4456%7C2c86bbfc8d0441ffa83a942f075e0f60%7C0&sdata=WPw4K5rRLrxK2DyDASTXhVor9k8z8%2FHdyTslCoR9i2U%3D&reserved=0> to activate access to content from 1999-current for all SAGE titles including new issues published during the period. To also benefit from a 25% discount on all SAGE books ordered online, go to the SAGE website (<https://emea01.safelinks.protection.outlook.com?url=http%3A%2F%2Fwww.sagepublications.com%2F&data=01%7C01%7C0selmasry%40uod.edu.sa%7Cb8cd7ef737e144cb8e5d08d4729e4456%7C2c86bbfc8d0441ffa83a942f075e0f60%7C0&sdata=mGBRHlONshncrd%2F%2B9zoHR4g%2BcmjYblA%2Foev9X3lPF8%3D&reserved=0>) and add the SAGE books that you would like to purchase to your shopping cart. When checking out, enter the Promotion Code GL10JR0001 when prompted. This will automatically deduct 25% from your final bill.

On behalf of the Editors of Tumor Biology, we appreciate the voluntary contribution that each reviewer gives to the Journal. We thank you for your participation in the online review process and hope that we may call upon you again to review future manuscripts.

Sincerely,  
Dr. James Radosevich  
Associate Editor, Tumor Biology  
jrados@uic.edu



## SPANDIDOS PUBLICATIONS

*International Journal of Oncology* ◇ *Oncology Reports* ◇ *Oncology Letters*  
*International Journal of Molecular Medicine* ◇ *Molecular Medicine Reports*  
*Experimental and Therapeutic Medicine* ◇ *Biomedical Reports*  
*Molecular and Clinical Oncology*

# Certificate of Excellence in Reviewing

awarded to

Dr Omar El-Masry

for their important contribution to the quality of our publication *Experimental and Therapeutic Medicine* on  
25/09/2018





## SPANDIDOS PUBLICATIONS

*International Journal of Oncology* ◊ *Oncology Reports* ◊ *Oncology Letters*  
*International Journal of Molecular Medicine* ◊ *Molecular Medicine Reports*  
*Experimental and Therapeutic Medicine* ◊ *Biomedical Reports*  
*Molecular and Clinical Oncology*

# Certificate of Excellence in Reviewing

awarded to

Dr Omar El-masry

for their important contribution to the quality of our publication *Experimental and Therapeutic Medicine* on  
12/08/2019





## SPANDIDOS PUBLICATIONS

*International Journal of Oncology* ◊ *Oncology Reports* ◊ *Oncology Letters*  
*International Journal of Molecular Medicine* ◊ *Molecular Medicine Reports*  
*Experimental and Therapeutic Medicine* ◊ *Biomedical Reports*  
*Molecular and Clinical Oncology*

# Certificate of Excellence in Reviewing

awarded to

Dr Omar El-Masry

for their important contribution to the quality of our publication *Oncology Letters* on 15/03/2019





## SPANDIDOS PUBLICATIONS

*International Journal of Oncology* ♦ *Oncology Reports* ♦ *Oncology Letters*  
*International Journal of Molecular Medicine* ♦ *Molecular Medicine Reports*  
*Experimental and Therapeutic Medicine* ♦ *Biomedical Reports*  
*Molecular and Clinical Oncology*

# Certificate of Excellence in Reviewing

awarded to

Dr Omar s. El-masry

for their important contribution to the quality of our publication *Molecular and Clinical Oncology* on  
10/06/2019





## SPANDIDOS PUBLICATIONS

*International Journal of Oncology* ♦ *Oncology Reports* ♦ *Oncology Letters*  
*International Journal of Molecular Medicine* ♦ *Molecular Medicine Reports*  
*Experimental and Therapeutic Medicine* ♦ *Biomedical Reports*  
*Molecular and Clinical Oncology*

# Certificate of Excellence in Reviewing

awarded to

Dr Omar S. El-Masry

for their important contribution to the quality of our publication *International Journal of Oncology* on  
04/04/2019





**SPANDIDOS PUBLICATIONS**

*International Journal of Oncology* ◊ *Oncology Reports* ◊ *Oncology Letters*  
*International Journal of Molecular Medicine* ◊ *Molecular Medicine Reports*  
*Experimental and Therapeutic Medicine* ◊ *Biomedical Reports*  
*Molecular and Clinical Oncology*

*Certificate of Excellence in Reviewing*

awarded to

**Dr Omar El-masry**

for their important contribution to the quality of our publication *Experimental and Therapeutic Medicine* on  
12/08/2019



**SPANDIDOS PUBLICATIONS**

*International Journal of Oncology* ◊ *Oncology Reports* ◊ *Oncology Letters*  
*International Journal of Molecular Medicine* ◊ *Molecular Medicine Reports*  
*Experimental and Therapeutic Medicine* ◊ *Biomedical Reports*  
*Molecular and Clinical Oncology*

*Certificate of Excellence in Reviewing*

awarded to

**Dr Omar El-masry**


for their important contribution to the quality of our publication *Molecular Medicine Reports* on 10/06/2019






SPANDIDOS  
PUBLICATIONS

## CERTIFICATE OF PEER REVIEW




for their important contribution to the quality of our publication *Molecular Medicine Reports* on 19/08/2020





SPANDIDOS  
PUBLICATIONS

## CERTIFICATE OF PEER REVIEW




for their important contribution to the quality of our publication *Molecular Medicine Reports* on 19/07/2020





SPANDIDOS  
PUBLICATIONS

## CERTIFICATE OF PEER REVIEW



for their important contribution to the quality of our publication *Molecular and Clinical Oncology* on


28/06/2020





SPANDIDOS  
PUBLICATIONS

## CERTIFICATE OF PEER REVIEW




for their important contribution to the quality of our publication *Oncology Letters* on 06/06/2020





SPANDIDOS  
PUBLICATIONS

## CERTIFICATE OF PEER REVIEW




for their important contribution to the quality of our publication *Molecular and Clinical Oncology* on  
12/04/2020





SPANDIDOS  
PUBLICATIONS

## CERTIFICATE OF PEER REVIEW



for their important contribution to the quality of our publication *Oncology Letters* on 09/01/2020





## SPANDIDOS PUBLICATIONS

*International Journal of Oncology* ◊ *Oncology Reports* ◊ *Oncology Letters*  
*International Journal of Molecular Medicine* ◊ *Molecular Medicine Reports*  
*Experimental and Therapeutic Medicine* ◊ *Biomedical Reports*  
*Molecular and Clinical Oncology*


# Certificate of Excellence in Reviewing

awarded to

Dr Omar El-masry


for their important contribution to the quality of our publication *Molecular Medicine Reports* on 03/09/2019





SPANDIDOS  
PUBLICATIONS

## CERTIFICATE OF PEER REVIEW




for their important contribution to the quality of our publication *Molecular Medicine Reports* on 19/08/2020





SPANDIDOS  
PUBLICATIONS


## CERTIFICATE OF PEER REVIEW



for their important contribution to the quality of our publication *Oncology Letters* on 12/10/2020



Appendix II: Ph.D. certificate & letter of work experience:









---

## Last Update

16/...10.../2024